News
AZ acquires rare disease specialist Alexion
AstraZeneca (AZ) has announced plans to acquire Alexion for approximately $39bn, gaining an ‘innovative’ rare disease pipeline in the process.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
AstraZeneca (AZ) has announced plans to acquire Alexion for approximately $39bn, gaining an ‘innovative’ rare disease pipeline in the process.